ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
In cancer patients, circulating tumor cells (CTCs) in the blood are the hallmark of the spread of the disease. But these cells are difficult to isolate because they are a tiny fraction of the total number of cells in blood. Medical engineer Mehmet Toner and coworkers at Massachusetts General Hospital and Harvard Medical School have now come up with a microfluidic device that isolates CTCs from whole blood samples (Nature 2007, 450, 1235).
The CTC chip consists of an array of micrometer-scale posts coated with antibodies against a molecule found on the surface of epithelial cells from various organs but not on blood cells. The researchers used the device to capture CTCs in blood samples from patients with lung, prostate, pancreatic, breast, or colon cancer. They were able to distinguish CTCs from blood cells and further analyze the captured CTCs for tumor-specific markers, such as prostate-specific antigen. In follow-up samples, the CTC measurements correlated with patients' clinical response to treatment.
The microfluidic device could become a tool for monitoring cancer treatment, for detecting relapses, and eventually for early detection, Toner says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X